Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Fennec Pharmaceuticals (FENC) over the last 15 years, with Q3 2025 value amounting to $27.9 million.

  • Fennec Pharmaceuticals' Shares Outstanding (Weighted Average) rose 189.25% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.9 million, marking a year-over-year increase of 189.25%. This contributed to the annual value of $27.3 million for FY2024, which is 270.94% up from last year.
  • According to the latest figures from Q3 2025, Fennec Pharmaceuticals' Shares Outstanding (Weighted Average) is $27.9 million, which was up 189.25% from $27.7 million recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $27.9 million during Q3 2025, and its lowest value of $26.0 million during Q1 2021.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $26.7 million, with a median of $26.6 million in 2023.
  • Per our database at Business Quant, Fennec Pharmaceuticals' Shares Outstanding (Weighted Average) soared by 3069.46% in 2021 and then rose by 6.15% in 2022.
  • Quarter analysis of 5 years shows Fennec Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $26.0 million in 2021, then grew by 1.03% to $26.3 million in 2022, then grew by 1.14% to $26.6 million in 2023, then rose by 2.71% to $27.3 million in 2024, then increased by 2.18% to $27.9 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $27.9 million for Q3 2025, versus $27.7 million for Q2 2025 and $27.6 million for Q1 2025.